Baker McKenzie

Healthcare & Life Sciences

Insight
13 January 2020
Global Transactions in the Healthcare & Life Sciences Sector: Fundamental Strengths to Drive Recovery from a Short-Term Slowdown
Though the healthcare and life sciences sector is not immune to the economic and geopolitical headwinds affecting all industries, its underlying strength will continue to promote dealmaking. 
Read More

Healthcare and life sciences are some of the largest and fastest-growing industries in the world, in addition to being the most regulated, with rapidly changing rules and regulations that often conflict from one country to another. Healthcare and life sciences companies face a number of challenges, including trying to understand how these laws impact their market and M&A strategies while contending with rising R&D costs, loss of patent protection of blockbuster drugs, pricing pressures, and competition from generics. Rapid convergence of the healthcare, life sciences and technology sectors requires even more legal expertise given the additional data privacy and intellectual property concerns.

Insight
February 2020
Coronavirus Resource Center
This hub is a central resource for all alerts and news developments related to the Coronavirus outbreak. 
Insight
18 February 2020
Coronavirus Outbreak: Force Majeure from a PRC Law Perspective
On 30 January 2020, the World Health Organisation declared the coronavirus outbreak a public health emergency of international concern.
Insight
12 February 2020
Asia Pacific Regional Update - Coronavirus Outbreak
Outline of employer obligations and important considerations across the Asia Pacific region in terms of dealing with the Coronavirus outbreak.
Insight
11 February 2020
Would the Novel Coronavirus Constitute a Force Majeure Event in Contracts Governed by Singapore Law?
Where a contract contains a force majeure clause, the touchstone is whether the outbreak falls within the scope of the clause.
Insight
10 February 2020
The Future of Capital Raising in Biotech and Pharma
Despite a decline in overall global activity, the biopharma sectors continue to perform strongly, bolstered by several factors. 
Insight
07 February 2020
Coronavirus: Crisis Management Through Force Majeure - A Hong Kong Law Perspective
The full impact of the outbreak and the resulting precautionary measures imposed by the PRC and Hong Kong governments remains to be seen.
Insight
05 February 2020
What Should Employers in China Be Doing in the Face of the Coronavirus Outbreak?
Companies operating in China have to find out what their obligations are under the law in the face of this outbreak and what should they be doing vis-à-vis their employees.
View All Insight
News
10 February 2020
US Continues to Lead in Biopharma Activity, China’s Rapid Pace of Innovation Ramps Up and Europe Continues as Solid Breeding Ground for Biopharma
The US continues to lead in terms of biotech and pharma activity on the capital markets.
News
30 January 2020
Baker McKenzie advises shareholders of Biopharma on the sale of pharmaceutical business to Stada AG
Baker McKenzie advised the shareholders of Biopharma on the carve-out of its non-plasma business and its further sale to Stada AG.
News
11 December 2019
Cross-Border Activity Slows Overall, But Domestic IPO Markets Buck Downward Trend
Our Cross-Border IPO Index 2019 finds that geopolitical uncertainties, particularly in major financial markets, dampened IPO activity and left investors waiting on the sidelines.
News
02 December 2019
Baker McKenzie Advises Pfizer in Restructuring and Joint Venture with GlaxoSmithKline in Mexico
The combination results in a world-leading consumer healthcare business.
News
14 November 2019
Novaliq and Jiangsu Hengrui Medicine Announce Strategic Collaboration
Baker McKenzie advises Novaliq in all legal aspects of the license agreement.
News
13 November 2019
UK consumer trust is proving a barrier to the adoption of digital healthcare technologies
Less than half (47%) of consumers trust digital health products.
News
05 November 2019
American Hospital Dubai partners with Livio in IVF joint venture
Under the agreement, the joint venture will establish an IVF center with a specialized laboratory as per Livio standards.
View All News
  • Ranked in the Top 10 Law Firms in the world for Life Sciences, Chambers Global
  • Ranked Band 1 for Life Sciences, Chambers Asia Pacific 2014-2018
  • Medical Law Firm of the Year, ALB Southeast Asia Awards 2017
  • Most Innovative Use of Technology for the Pharma MapApp, FT Most Innovative Lawyer Awards, 2015
  • No. 1 Healthcare M&A firm by deal volume for past three years, Thomson Reuters 2017
  • No. 1 Healthcare M&A firm by cross-border deal volume for past five years, Thomson Reuters 2017

 

How We Can Help

About Us

Learn about our Global Healthcare & Life Sciences Industry Group in 3 minutes

Healthcare MapApp

Access real-time information on the laws and regulations affecting the healthcare and life sciences industries in more than 50 countries

Global Healthcare and Life Sciences Webinar Series

Learn about a spectrum of legal issues and hot topics in the healthcare and life sciences industries

Clinical Trials Handbook

Outlines the legal framework governing clinical trials of medicinal products in 34 jurisdictions

Promoting Medical Products Globally

Understand legal developments and regulations related to ethical business interactions between medical companies and healthcare professionals in 35 countries

Key Contacts

We use cookies on our website. To learn more about how we use cookies and how to change your cookies settings if you do not want cookies on your computer, please see our Privacy and Cookies Statement. By continuing to use this site you consent to our use of cookies in accordance with our Privacy and Cookies Statement.
View Statement